Skip to content

The effect of bronchodilators on lung ventilation in chronic obstructive pulmonary disease

The effect of tiotropium bromide on ventilation perfusion heterogeneity in chronic obstructive pulmonary disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12607000482460
Enrollment
15
Registered
2007-09-21
Start date
2007-08-04
Completion date
2008-08-04
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Chronic Obstructive Pulmonary Disease (COPD) is a common disorder which causes changes within the airways and blood vessels of the lung. As a result of these changes, it can cause problems with breathing and the way air and oxygen travels to different parts of the lung. We have several different ways of looking at how bad COPD is, however none of these are perfect. By understanding better the way in which airways behave in COPD, and the effects this has on blood flow within the lung, the better able we will be to investigate, develop new medications, and treat COPD. In this study we will be investigating the way COPD affects breathing and blood flow by looking at changes in lung function. We will then compare this information with pictures of breathing and blood flow obtained from a nuclear medicine scan.

Interventions

Washout period is one week between interventions. Single dose of 18µg tiotropium bromide and 200µg salbutamol. Both drugs are inhaled

Sponsors

The Woolcock Institute of Medical Research
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
40 Years to -2147483648 No limit
Healthy volunteers
No

Inclusion criteria

Subjects must have a doctor diagnosis of COPD, greater than 15pack year smoking history and obstructed lung function that cannot be normalised with bronchodilator. Subjects must all be over the age of 50 with no history of asthma or allergic disease. Minimum age: 50 years for females and 40 years for males

Exclusion criteria

Females under the age of 50years

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026